RxDoctor Payments Data

David Tanner, DO

General Practice · Newport, PANPI 1629032776

Payments from drug & device makers

$339in general payments, 2019–2025

Across 8 payments — averaging $42.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$122
  • AbbVie$122
  • Novo Nordisk$18
  • Pfizer$17
  • AstraZeneca$16
  • Covis Pharma GmbH$16
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker1$122
AbbVie1$122
Novo Nordisk1$18
Pfizer1$17
AstraZeneca1$16
Covis Pharma GmbH1$16
Medtronic1$15
GSK1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$339 in reported general payments places this provider in the 65th percentile of 3,208 general practice providers in Pennsylvania.

See all general practice providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,627
Medicare patients
71
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$35,604
JanuviaSitagliptin Phosphate27$31,964
OzempicSemaglutide11$10,553
JardianceEmpagliflozin14$7,796
LinzessLinaclotide12$7,389
CreonLipase/Protease/Amylase13$4,441
SymbicortBudesonide/Formoterol Fumarate12$2,692
Ventolin HfaAlbuterol Sulfate45$2,499
Albuterol Sulfate HfaAlbuterol Sulfate44$1,981
Tamsulosin Hcl66$1,976
Ezetimibe120$1,976
Lisinopril184$1,898
Potassium Chloride113$1,875
Levothyroxine Sodium172$1,707
Candesartan Cilexetil14$1,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$35,60443 claims
AbbVieLinzess, Creon$122$11,82925 claims
Novo NordiskOzempic$18$10,55311 claims
AstraZenecaSymbicort$16$2,69212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,208 general practice providers in Pennsylvania.

Other general practice in Newport

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →